187 related articles for article (PubMed ID: 10465111)
41. Mutational analysis of the P16-binding domain of cyclin-dependent kinase 4 in tumors in the head region of the pancreas.
Ceha HM; Clement MJ; Polak MM; Offerhaus GJ; Slebos RJ
Pancreas; 1998 Jul; 17(1):85-8. PubMed ID: 9667525
[TBL] [Abstract][Full Text] [Related]
42. Lack of evidence of Ki-ras codon 12 mutations in melanocytic lesions.
Albino AP; Nanus DM; Davis ML; McNutt NS
J Cutan Pathol; 1991 Aug; 18(4):273-8. PubMed ID: 1939786
[TBL] [Abstract][Full Text] [Related]
43. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.
Zuo L; Weger J; Yang Q; Goldstein AM; Tucker MA; Walker GJ; Hayward N; Dracopoli NC
Nat Genet; 1996 Jan; 12(1):97-9. PubMed ID: 8528263
[No Abstract] [Full Text] [Related]
44. p53 gene mutation and expression in naevi and melanomas.
Sparrow LE; Soong R; Dawkins HJ; Iacopetta BJ; Heenan PJ
Melanoma Res; 1995 Apr; 5(2):93-100. PubMed ID: 7620345
[TBL] [Abstract][Full Text] [Related]
45. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
46. Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas.
Tse JY; Ng HK; Lo KW; Chong EY; Lam PY; Ng EK; Poon WS; Huang DP
Hum Pathol; 1998 Nov; 29(11):1200-7. PubMed ID: 9824096
[TBL] [Abstract][Full Text] [Related]
47. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 7-2004. A 48-year-old woman with multiple pigmented lesions and a personal and family history of melanoma.
Tsao H; Sober AJ; Niendorf KB; Zembowicz A
N Engl J Med; 2004 Feb; 350(9):924-32. PubMed ID: 14985491
[No Abstract] [Full Text] [Related]
48. American Academy of Dermatology 1999 Awards for Young Investigators in Dermatology. Targets of genetic injury in cutaneous melanoma.
Tsao H
J Am Acad Dermatol; 1999 Sep; 41(3 Pt 1):459-61. PubMed ID: 10507912
[No Abstract] [Full Text] [Related]
49. Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.
Vax VV; Bibi R; Diaz-Cano S; Gueorguiev M; Kola B; Borboli N; Bressac-de Paillerets B; Walker GJ; Dedov II; Grossman AB; Korbonits M
J Endocrinol; 2003 Aug; 178(2):301-10. PubMed ID: 12904177
[TBL] [Abstract][Full Text] [Related]
50. Sporadic p53 mutations and absence of ras mutations in glioblastomas.
Gömöri E; Dóczi T; Pajor L; Matolcsy A
Acta Neurochir (Wien); 1999; 141(6):593-9. PubMed ID: 10929724
[TBL] [Abstract][Full Text] [Related]
51. Melanocortin-1 receptor (MC1R) genotypes do not correlate with size in two cohorts of medium-to-giant congenital melanocytic nevi.
Calbet-Llopart N; Pascini-Garrigos M; Tell-Martí G; Potrony M; Martins da Silva V; Barreiro A; Puig S; Captier G; James I; Degardin N; Carrera C; Malvehy J; Etchevers HC; Puig-Butillé JA
Pigment Cell Melanoma Res; 2020 Sep; 33(5):685-694. PubMed ID: 32323445
[TBL] [Abstract][Full Text] [Related]
52. Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients.
Kitamura F; Araki S; Suzuki Y; Yokoyama K; Tanigawa T; Iwasaki R
Ind Health; 2002 Apr; 40(2):175-81. PubMed ID: 12064559
[TBL] [Abstract][Full Text] [Related]
53. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin.
Jiveskog S; Ragnarsson-Olding B; Platz A; Ringborg U
J Invest Dermatol; 1998 Nov; 111(5):757-61. PubMed ID: 9804334
[TBL] [Abstract][Full Text] [Related]
54. Identification of a CDK4 R24H mutation-positive melanoma family by analysis of early-onset melanoma patients in Latvia.
Pjanova D; Molven A; Akslen LA; Engele L; Streinerte B; Azarjana K; Heisele O
Melanoma Res; 2009 Apr; 19(2):119-22. PubMed ID: 19238106
[TBL] [Abstract][Full Text] [Related]
55. Ras oncogenes and p53 tumor suppressor gene analysis in cardiac myxomas.
Karga H; Papaioannou P; Karayianni M; Papadimitriou K; Priftis D; Voujuklakis T; Migdou B; Nanas J; Papapetrou P
Pathol Res Pract; 2000; 196(9):601-5. PubMed ID: 10997733
[TBL] [Abstract][Full Text] [Related]
56. Normal repair of ultraviolet radiation-induced DNA damage in familial melanoma without CDKN2A or CDK4 gene mutation.
Shannon JA; Matias C; Luxford C; Kefford RF; Mann GJ
Melanoma Res; 1999 Apr; 9(2):133-7. PubMed ID: 10380935
[TBL] [Abstract][Full Text] [Related]
57. Rarity of CDK4 germline mutations in familial melanoma.
Goldstein AM; Chidambaram A; Halpern A; Holly EA; Guerry IV D; Sagebiel R; Elder DE; Tucker MA
Melanoma Res; 2002 Feb; 12(1):51-5. PubMed ID: 11828258
[TBL] [Abstract][Full Text] [Related]
58. Arsenic-related Bowen's disease and paraquat-related skin cancerous lesions show no detectable ras and p53 gene alterations.
Hsieh LL; Chen HJ; Hsieh JT; Jee SH; Chen GS; Chen CJ
Cancer Lett; 1994 Oct; 86(1):59-65. PubMed ID: 7954356
[TBL] [Abstract][Full Text] [Related]
59. How is the mutational status for tumor suppressors p53 and p16(INK4A) in MFH of the bone?
Taubert H; Berger D; Hinze R; Meye A; Würl P; Hogendoorn PC; Holzhausen HJ; Schmidt H; Rath FW
Cancer Lett; 1998 Jan; 123(2):147-51. PubMed ID: 9489481
[TBL] [Abstract][Full Text] [Related]
60. Analysis of the CDKN2A and CDK4 genes and HLA-DR and HLA-DQ alleles in two Spanish familial melanoma kindreds.
Nagore E; Climent J; Planelles MD; Ledesma E; Rubio-Moscardó F; Fortea JM; Oliver V
Acta Derm Venereol; 2000; 80(6):440-2. PubMed ID: 11243640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
